Long-lived Impurities of 90Y-labeled Microspheres, TheraSphere and SIR-Spheres, and the Impact on Patient Dose and Waste Management

Metyko, John; Williford, John M.; Erwin, William D.; Poston, J.W.; Jimenez, Sandra

doi:10.1097/hp.0b013e31826566f0

Cited by 20 publications

(16 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yttrium-90 is a beta emitter radioisotope (E max = 2.28 MeV) with a half-life of 64 h. This radionuclide has been widely studied as a potential agent for radiation synovectomy [16,17], and also showed a good stability for 90 Y-HA preparation for in vitro applications [17]. In addition, this radioisotope has been used in brachytherapy to treat metastatic liver tumors in microspheres labeled systems [18,19].…”

Section: Open Access Jbnbmentioning

confidence: 99%

Poly(Vinyl Alcohol)/Collagen/Hydroxyapatite Nanoparticles Hybrid System Containing Yttrium-90 as a Potential Agent to Treat Osteosarcoma

Cipreste¹,

Sousa²

2014

JBNB

View full text Add to dashboard Cite

Osteosarcoma is the most common primary malignant bone tumors, affecting mostly children, adolescents and young adults. This is an aggressive tumor that results in a high mortality rate and poor prognosis. Due to the low sensitivity of osteosarcoma to ionizing radiation, such treatment is not used very often and it can be recommended only to postsurgical therapy. As an alternative therapy, functionalized nanomaterials allow their accumulation in tumor tissues due to their unique properties, making them good agents to act as stable carriers for radionuclides. In this work, mesoporous hydroxyapatite nanoparticles were synthesized and the functionalization process with poly(vinyl alcohol) and collagen was investigated. The samples were characterized by X-ray diffraction (XRD), N 2 adsorption, elemental analysis (CHN), Fourier Transform Infrared Spectroscopy (FTIR), Nitrogen Adsorption, Transmission Electron Microscopy (TEM), and Thermal Analysis. Also, the yttrium incorporation potential and its release kinetics in the hydroxyapatite matrix were evaluated to study the capacity of this system to treat osteosarcomas. The results indicate that this material has a promisor potential to treat this kind of tumor.

show abstract

Section: Open Access Jbnbmentioning

confidence: 99%

Poly(Vinyl Alcohol)/Collagen/Hydroxyapatite Nanoparticles Hybrid System Containing Yttrium-90 as a Potential Agent to Treat Osteosarcoma

Cipreste¹,

Sousa²

2014

JBNB

View full text Add to dashboard Cite

show abstract

“…gamma-emitting impurities in SIR-Spheres (Metyko et al 2012). No gamma-emitting impurities were detected in the Zevalin sample.…”

Section: Resultsmentioning

confidence: 88%

“…A very similar setup was employed in the previous TheraSphere and SIR-Spheres analysis (Metyko et al 2012). The sample was contained in a syringe and counted for approximately one day at near contact with the detector.…”

Section: Methodsmentioning

confidence: 99%

“…NRC 2007). Related studies have been published since then, focusing on the long-lived, gamma-emitting impurities and ultimately confirming the impurity quantities specified in vendor provided documentation (Nelson et al 2008;Metyko et al 2012). To date, no publications quantify pure beta-emitting impurities, specifically 90 Sr, whose presence would be expected with 90 Sr/ 90 Y generator production methods.…”

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

90Sr Content in 90Y-labeled SIR-Spheres and Zevalin

Metyko¹,

Erwin²,

Poston³

et al. 2014

Health Physics

Self Cite

View full text Add to dashboard Cite

Three different 90Y internally administered radionuclide therapies are currently used in both standard-of-care and clinical trial procedures atMD Anderson Cancer Center. TheraSphere and SIR-Spheres therapies utilize 90Y-labeled microspheres, while Zevalin is an 90Y-labeled radioimmunotherapeutic agent. Several publications have indicated radionuclidic impurities resulting from 90Y production methods. The 90Y in SIR-Spheres and Zevalin are produced from a 90Sr/90Y generator, which leaves measurable quantities of 90Sr in the final product. TheraSphere 90Y is produced in a nuclear reactor which results in a large number of impurities, most notably 88Y and 91Y. Product information sheets reference these impurities with specific limits given. These limits represent a tiny fraction of the total product activity, and in the case of TheraSphere and SIR-Spheres gamma-emitting impurities, this has been verified in the literature. An analysis of 90Sr impurities in SIR-Spheres and Zevalin is presented in this paper. Impurity quantities were found to be within the vendors’ documented limits.

show abstract

“…There have been many literature publications comparing the performance of the two spheres with equal efficacy [16][17][18][19]. The dose for SIRT treatment has been mostly estimated using computed tomography (CT) images [20][21][22][23].…”

Section: Y-90 Microparticlesmentioning

confidence: 99%

Positron Emission Tomography (PET) Tumor Segmentation and Quantification: Development of New Algorithms

Bhatt¹

View full text Add to dashboard Cite

Professor Anthony McGoron, Major ProfessorTumor functional volume (FV) and its mean activity concentration (mAC) are the quantities derived from positron emission tomography (PET). These quantities are used for estimating radiation dose for a therapy, evaluating the progression of a disease and also use it as a prognostic indicator for predicting outcome. PET images have low resolution, high noise and affected by partial volume effect (PVE). Manually segmenting each tumor is very cumbersome and very hard to reproduce. To solve the above problem I developed an algorithm, called iterative deconvolution thresholding segmentation (IDTS) algorithm; the algorithm segment the tumor, measures the FV, correct for the PVE and calculates mAC. The algorithm corrects for the PVE without the need to estimate camera's point spread function (PSF); also does not require optimizing for a specific camera. My algorithm was tested in physical phantom studies, where hollow spheres (0.5-16 ml) were used to represent tumors with a homogeneous activity distribution. It was also tested on irregular shaped tumors with a heterogeneous activity profile which were acquired using physical and simulated phantom. The physical phantom studies were performed with different signal to background ratios (SBR) and iv with different acquisition times (1-5 min). The algorithm was applied on ten clinical data where the results were compared with manual segmentation and fixed percentage thresholding method called T50 and T60 in which 50% and 60% of the maximum intensity respectively is used as threshold. The average error in FV and mAC calculation was 30% and -35% for 0.5 ml tumor. The average error FV and mAC calculation were ~5% for 16 ml tumor. The overall FV error was ~10% for heterogeneous tumors in physical and simulated phantom data. The FV and mAC error for clinical image compared to manual segmentation was around -17% and 15% respectively. In summary my algorithm has potential to be applied on data acquired from different cameras as its not dependent on knowing the camera's PSF. The algorithm can also improve dose estimation and treatment planning.

show abstract

Long-lived Impurities of 90Y-labeled Microspheres, TheraSphere and SIR-Spheres, and the Impact on Patient Dose and Waste Management

Cited by 20 publications

References 3 publications

Poly(Vinyl Alcohol)/Collagen/Hydroxyapatite Nanoparticles Hybrid System Containing Yttrium-90 as a Potential Agent to Treat Osteosarcoma

Poly(Vinyl Alcohol)/Collagen/Hydroxyapatite Nanoparticles Hybrid System Containing Yttrium-90 as a Potential Agent to Treat Osteosarcoma

90Sr Content in 90Y-labeled SIR-Spheres and Zevalin

Positron Emission Tomography (PET) Tumor Segmentation and Quantification: Development of New Algorithms

Contact Info

Product

Resources

About